MANIPULATION OF CD40 CD40L IN CTL BASED IMMUNOTHERAPY
MANIPULATION OF CD40 CD40L IN CTL BASED IMMUNOTHERAPY
批准号:
6633385
负责人:
Stephen Philip Schoenberger
金额:
$25.38万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-04-01 至 2005-03-31
关键词:
CD40 molecule antigen presenting cell autoimmunity cytotoxic T lymphocyte disease /disorder model genetic promoter element genetically modified animals insulin kidney disorder laboratory mouse leukocyte activation /transformation model design /development neoplasm /cancer immunotherapy ovalbumin pancreas neoplasms tumor antigens
中文摘要
说明:(申请人摘要)癌症的成功应用
免疫治疗需要对CD 8+细胞毒性T细胞更深入了解
淋巴细胞(CTL)调节,以便有效地控制肿瘤生长,
限制自身免疫损伤。CTL激活途径的研究进展
和耐受性表明,内源性或转染的CTL群体可以被
在抗原呈递细胞(APC)功能水平上进行体内控制
通过操纵CD 40-CD 40 L相互作用。对此,显然有
需要自发性癌症的生理学相关动物模型,
将允许研究这些肿瘤免疫系统的相互作用,并允许
APC聚焦免疫策略的有用评估。这个目标
研究是开发这样一个强大的新模型系统,其中的能力
APC调节肿瘤特异性CD 8+细胞毒性和CD 4+辅助性T细胞
可以在原发性内源性肿瘤的发展过程中评估反应
表达模型自身抗原。这种肿瘤模型的一部分涉及转基因
在大鼠的控制下表达有效的SV 40 T抗原癌基因的小鼠
胰岛素启动子(RIP-Tag 2)。RIP-Tag 2小鼠发生胰腺β细胞肿瘤
导致自主胰岛素分泌和致死性低血糖,
个月RIP-Tag 2小鼠将与表达卵清蛋白的RIP-mOVA小鼠杂交
(OVA)作为胰腺和近端肾小管β细胞中的自身抗原
肾脏的细胞在RIP-mOVA小鼠中,OVA有效地交叉呈递在
宿主APC,导致OVA特异性CTL的缺失,其可被
CD 4 + OVA特异性辅助T细胞。转基因OVA特异性CTL(OT-I细胞)将
在培养期间的不同时间过继转移至RIP(Tag 2 x mOVA)小鼠。
表达OVA的β细胞肿瘤的发展。CTL的能力,
控制肿瘤生长与引起自身免疫损伤的对比将通过i)
监测血糖水平(反映肿瘤负荷和自身免疫
破坏正常β细胞),ii)胰腺的组织学检查,和
肾,iii)转移的CTL的持久性和活化/耐受化
(体外测量),和iv)对存活的影响。以亚太经合组织为重点的
将使用OVA特异性CD 4 + T细胞或刺激性T细胞尝试OT-I细胞。
抗-CD 40抗体诱导和维持OT-I细胞和抑制
抗-CD 40 L抗体以下调OT-I细胞的应答。希望
这个项目将产生一个上级的动物模型,
影响肿瘤控制和自身免疫之间平衡的因素
基于CTL的免疫疗法
英文摘要
DESCRIPTION: (Applicant's Abstract) The successful application of cancer
immunotherapy will require a deeper understanding of CD8+ cytotoxic T
lymphocyte (CTL) regulation in order to effectively control tumor growth while
limiting autoimmune damage. Recent insights into the pathways of CTL activation
and tolerance suggests that endogenous or transfected CTL populations can be
controlled in vivo at the level of antigen-presenting cell (APC) function
through manipulation of CD40-CD40L interactions. Towards this, there is clearly
a need for physiologically relevant animal models of spontaneous cancer that
will allow the study of these tumor-immune system interactions and permit a
useful evaluation of APC-focused immunotherapeutic strategies. The goal of this
research is to develop such a powerful new model system in which the capacity
of APC to regulate tumor-specific CD8+ cytotoxic and CD4+ helper T cell
responses can be assessed during the development of a primary endogenous tumor
expressing a model self-antigen. Part of this tumor model involves transgenic
mice expressing the potent SV40 T antigen oncogene under the control of the rat
insulin promoter (RIP-Tag2). RIP-Tag2 mice develop pancreatic beta-cell tumors
leading to autonomous insulin secretion and lethal hypoglycemia within 3-4
months. RIP-Tag2 mice will be crossed with RIP-mOVA mice that express ovalbumin
(OVA) as a self-antigen in beta cells of the pancreas and proximal tubular
cells of the kidney. In RIP-mOVA mice, OVA is efficiently cross-presented on
host APC, leading to the deletion of OVA-specific CTL which can be blocked by
CD4+ OVA-specific helper T cells. Transgenic OVA-specific CTL (OT-I cells) will
be adoptively transferred to the RIP(Tag2 x mOVA) mice at various times during
the development of OVA-expressing beta cell tumors. The ability of the CTL to
control tumor growth versus causing autoimmune damage will be examined by i)
monitoring of blood glucose levels (reflecting tumor burden and autoimmune
destruction of normal beta cells), ii) histological examination of pancreas and
kidneys, iii) the persistence, and activation/tolerization of transferred CTL
(measured in vitro), and iv) effect on survival. APC-focused regulation of the
OT-I cells will be attempted using OVA-specific CD4+ T cells or stimulatory
anti-CD40 antibodies to induce and maintain OT-I cells and inhibitory
anti-CD40L antibodies to tune down the responses of OT-I cells. It is hoped
that this project will result in a superior animal model in which to explore
factors that influence the balance between tumor control and autoimmunity in
CTL-based immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer
-
批准号:10718057
-
项目类别:
-
资助金额:$62.92万
-
财政年份:2023
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
-
批准号:8990833
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2014
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Local control of anti-tumor/anti-self reactivity in low-affinity ACT
-
批准号:8810185
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2014
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Cellular and Molecular Regulation of CD8+ T cell memory
-
批准号:8563544
-
项目类别:
-
资助金额:$41.6万
-
财政年份:2013
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Cellular and Molecular Regulation of CD8+ T cell memory
-
批准号:9047234
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Cellular and Molecular Regulation of CD8+ T cell memory
-
批准号:8660287
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2013
-
负责人:Stephen Philip Schoenberger
-
依托单位:
2009 Antigen Cross Presentation Gordon-sponsored Meeting
-
批准号:7671922
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2009
-
负责人:Stephen Philip Schoenberger
-
依托单位:
La Jolla Immunology Conference
-
批准号:8322085
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2008
-
负责人:Stephen Philip Schoenberger
-
依托单位:
La Jolla Immunology Conference
-
批准号:8597885
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2008
-
负责人:Stephen Philip Schoenberger
-
依托单位:
La Jolla Immunology Conference
-
批准号:8088081
-
项目类别:
-
资助金额:$0.85万
-
财政年份:2008
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Programming of CD8+ T Cell Tolerance by B Cell APC
-
批准号:7428877
-
项目类别:
-
资助金额:$46.0万
-
财政年份:2007
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Programming of CD8+ T Cell Tolerance by B Cell APC
-
批准号:7881625
-
项目类别:
-
资助金额:$45.37万
-
财政年份:2007
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Programming of CD8+ T Cell Tolerance by B Cell APC
-
批准号:8078819
-
项目类别:
-
资助金额:$44.92万
-
财政年份:2007
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Programming of CD8+ T Cell Tolerance by B Cell APC
-
批准号:7623612
-
项目类别:
-
资助金额:$61.33万
-
财政年份:2007
-
负责人:Stephen Philip Schoenberger
-
依托单位:
Programming of CD8+ T Cell Tolerance by B Cell APC
-
批准号:7303051
-
项目类别:
-
资助金额:$48.76万
-
财政年份:2007
-
负责人:Stephen Philip Schoenberger
-
依托单位:
MANIPULATION OF CD40 CD40L IN CTL BASED IMMUNOTHERAPY
-
批准号:6132948
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2000
-
负责人:Stephen Philip Schoenberger
-
依托单位:
TRAIL-mediated regulation of T help for CTL
-
批准号:7056152
-
项目类别:
-
资助金额:$29.19万
-
财政年份:2000
-
负责人:Stephen Philip Schoenberger
-
依托单位:
TRAIL-mediated regulation of T help for CTL
-
批准号:6935707
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2000
-
负责人:Stephen Philip Schoenberger
-
依托单位:
TRAIL-mediated regulation of T help for CTL
-
批准号:7588083
-
项目类别:
-
资助金额:$28.34万
-
财政年份:2000
-
负责人:Stephen Philip Schoenberger
-
依托单位:
MANIPULATION OF CD40 CD40L IN CTL BASED IMMUNOTHERAPY
-
批准号:6721369
-
项目类别:
-
资助金额:$25.38万
-
财政年份:2000
-
负责人:Stephen Philip Schoenberger
-
依托单位:
海外基金